Notwithstanding the evidence supporting a role for the PAC1 receptor in migraine, it cannot be completely ruled out that the differences in migraine-generation properties of PACAP and VIP are rather due to their pharmacokinetic characteristics (difference in half-life) than due to differences in their pharmacodynamic action. Here, ADCYAP1 is linked to migraine disorder.